Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) shares saw strong trading volume on Tuesday . 4,293,116 shares traded hands during trading, an increase of 343% from the previous session's volume of 969,901 shares.The stock last traded at $5.68 and had previously closed at $4.75.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Wednesday. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $18.60.
Get Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Stock Performance
The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The stock's 50 day simple moving average is $3.40 and its two-hundred day simple moving average is $3.49. The stock has a market cap of $492.19 million, a P/E ratio of -5.88 and a beta of 0.88.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. As a group, research analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current year.
Institutional Trading of Atyr PHARMA
A number of institutional investors have recently made changes to their positions in ATYR. D.A. Davidson & CO. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $141,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $144,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $37,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $88,000. Institutional investors own 61.72% of the company's stock.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
